Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 22, 2021

SELL
$35.66 - $42.94 $336,452 - $405,138
-9,435 Closed
0 $0
Q2 2021

Aug 26, 2021

BUY
$23.7 - $39.27 $1,896 - $3,141
80 Added 0.86%
9,435 $370,000
Q1 2021

Apr 28, 2021

BUY
$27.01 - $36.8 $7,724 - $10,524
286 Added 3.15%
9,355 $264,000
Q4 2020

Jan 28, 2021

BUY
$27.51 - $34.36 $12,076 - $15,084
439 Added 5.09%
9,069 $290,000
Q3 2020

Oct 30, 2020

BUY
$25.8 - $34.61 $6,063 - $8,133
235 Added 2.8%
8,630 $278,000
Q2 2020

Jul 31, 2020

BUY
$17.65 - $28.05 $148,171 - $235,479
8,395 New
8,395 $231,000
Q2 2019

Aug 02, 2019

SELL
$22.0 - $31.78 $164,230 - $237,237
-7,465 Closed
0 $0
Q1 2019

May 02, 2019

BUY
$21.27 - $30.58 $158,780 - $228,279
7,465 New
7,465 $0
Q4 2018

Feb 06, 2019

SELL
$23.09 - $37.69 $161,606 - $263,792
-6,999 Closed
0 $0
Q3 2018

Nov 01, 2018

BUY
$26.55 - $34.38 $10,354 - $13,408
390 Added 5.9%
6,999 $209,000
Q2 2018

Aug 01, 2018

BUY
$27.79 - $34.49 $277 - $344
10 Added 0.15%
6,609 $210,000
Q1 2018

May 01, 2018

BUY
$28.87 - $41.13 $2,309 - $3,290
80 Added 1.23%
6,599 $222,000
Q3 2017

Nov 06, 2017

BUY
$22.15 - $27.5 $144,395 - $179,272
6,519
6,519 $203,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.